Construction of human antibody gene libraries and selection of antibodies by phage display.
Recombinant antibodies as therapeutics offer new opportunities for the treatment of many tumor diseases. To date, 18 antibody-based drugs are approved for cancer treatment and hundreds of anti-tumor antibodies are under development. The first clinically approved antibodies were of murine origin or human-mouse chimeric. However, since murine antibody domains are immunogenic in human patients and could result in human anti-mouse antibody (HAMA) responses, currently mainly humanized and fully human antibodies are developed for therapeutic applications.Here, in vitro antibody selection technologies directly allow the selection of human antibodies and the corresponding genes from human antibody gene libraries. Antibody phage display is the most common way to generate human antibodies and has already yielded thousands of recombinant antibodies for research, diagnostics and therapy. Here, we describe methods for the construction of human scFv gene libraries and the antibody selection.
Schirrmann
Thomas
T
Department of Biotechnology, Institute of Biochemistry and Biotechnology, Technische Universität Braunschweig, Braunschweig, Germany.
Hust
Michael
M
D000906:Antibodies / Q000235:genetics*; D004797:Enzyme-Linked Immunosorbent Assay; D015723:Gene Library; D006801:Humans; D008967:Molecular Biology / Q000379:methods*; D019151:Peptide Library; D019065:Virus Assembly
D000906:Antibodies; D019151:Peptide Library